EdgeTestMarket TodayOptions TodayIPO
Start free

SURAKSHASuraksha Diagnostic Limited

Rs 312.65▲ +4.44%
Market closedEquity EOD 26 Oct
Compare
52-week rangeThe lowest and highest prices the stock traded at over the last year, from each day's intraday low and high. The marker is today's close: 0% means it sits at the year's low, 100% at the high. It describes where the price is, not where it is going.65.2% up the range
Rs 224Rs 360
SURAKSHA price
Daily candles, adjusted for splits and bonus issues so a corporate action does not show as a crash. Pick a window from one month to the full history, add indicators, or open it full screen.
EOD 26 Oct
IndicatorsVolume

Loading SURAKSHA price...

At a glance
Each figure is shown against the company's sector (the track: the dot is this company, the tick is the sector middle) and, where we hold the yearly filings, against its own recent years (the small trend line).
Market capWhat the whole company is worth on the stock market today: share price times the number of shares. It measures size, not quality.
Rs 1,628 cr
Larger than 38% of 8 peers
sector middle Rs 6,793 cr
P/EPrice to earnings: how many rupees investors pay for each rupee of profit the company made over the last twelve months. Compare it with similar companies rather than reading it alone.
45.4x
Higher than 80% of 5 peers
sector middle 27.6x
Price to bookPrice to book: the share price divided by the shareholders' money per share in the latest balance sheet. Around 1 means the market values the company close to its book value.
6.7x
Around the middle of 8 peers
sector middle 6.4x
ROEReturn on equity: the year's profit as a percentage of the shareholders' money in the business. It shows how much the company earns on what its owners have put in.
14.4%
Around the middle of 6 peers
sector middle 16.4%
ROCEReturn on capital employed: operating profit as a percentage of all the long-term money in the business, owners' and lenders'. It shows how well the company uses its capital, whatever the mix of debt.
14.7%
Lower than 71% of 7 peers
sector middle 19.2%
FY25 17.1%FY26 14.7%
Debt to equityBorrowings divided by shareholders' money. 0 means no borrowings; 1 means it owes as much as its owners have put in. Not shown for banks and lenders, whose borrowing is their business.
0.01
Around the middle of 7 peers
sector middle 0.01
FY25 0.03FY26 0.01
Dividend yieldDividends paid over the last year as a percentage of the company's market value: roughly what Rs 100 of shares paid out in cash.
0.0%
Lower than 62% of 8 peers
sector middle 0.2%
Sales growthHow much the latest quarter's sales grew against the same quarter a year earlier.
+20.8%
Lower than 67% of 6 peers
sector middle +22.4%

Peers are the listed companies in the exchange's own industry group: Healthcare Service Provider. Balance-sheet figures are from the latest filed balance sheet; trends show each financial year we hold.

What the numbers say
Short lines written by fixed rules from the company's own filings and shareholding. A line appears only when the figures cross the rule (for example sales growing three years running), and each names the numbers behind it. Nothing here is a view on whether to own the share.

Latest quarterIn the quarter to June 2026 (results filed 13 Aug 2026), sales rose 20.7% from a year earlier to Rs 87.6 cr and profit rose 40.0% to Rs 12.8 cr.

Nothing in the filings we hold crosses one of our rules yet. Each rule needs a few complete years of results, so recently listed companies often show nothing here.

Each line is written by a fixed rule from the company's own filings and share price, and names the figures it uses. It describes what happened; it is not advice about the share.

How the share moved on results
For each quarterly result we hold: the change from the share's close on the last trading day before the filing to its close on the first trading day after it. Results can land during market hours or after the close, and this window covers both. It shows what happened, not what will happen next time.

Over the last 7 results, the share rose on 4 and fell on 3, and moved by 3% or more on 2.

Q2 FY25Q1 FY26Q1 FY27

Q1 FY27: results filed 13 Aug 2026. The share went from its close on 12 Aug 2026 to its close on 14 Aug 2026 +12.78%.

Fundamentals
Trailing-twelve-month valuation, margins and growth from the company's own filings.
as of 2026-06-30
P/E (TTM)
45.4
PEG
1.14
EPS (TTM)
Rs 6.9
Net margin
10.8%
Rev growth YoY
+20.75%
Profit growth YoY
+40.00%
TTM revenue
Rs 326 Cr
TTM net profit
Rs 35 Cr
Health check, year by year
Returns and debt for each financial year from the March balance sheet, each row coloured against this company's own usual level.
MeasureFY25FY26
ROCEOperating profit as a percentage of all long-term capital, owners' and lenders'.17.1%14.7%
Debt to equityBorrowings divided by shareholders' money. Lower is safer.0.03x0.01x

Each row is coloured against this company's own usual level, not against other companies: green is better than its middle year, red worse, plain is close to it. ROE, ROCE and debt rows start once the filings carry a full balance sheet (FY22 at the earliest).

What it owns, and how that is paid for
Straight from the March balance sheet in the company's annual filing. Both bars are the whole balance sheet: what the company owns, and where the money for it came from.
as at 2026-03-31

At FY26 it owned Rs 448 Cr of assets. Its owners funded 54% of that and borrowings 0%.

What it owns
51%
27%
9%
Plant, property and projects229 Cr
Goodwill and intangibles121 Cr
Inventory8 Cr
Owed by customers23 Cr
Cash and bank26 Cr
Everything else41 Cr
How that is paid for
54%
41%
Shareholders243 Cr
Borrowings2 Cr
Owed to suppliers21 Cr
Other liabilities182 Cr
Cash and equivalents
Rs 3 Cr
Net debt
Rs -1 Cr
more cash than debt
Current ratio
1.05x
short-term assets per rupee due soon
Book value / share
Rs 47
Return on assets
7.8%
EV / EBITDA
16.5x

From the March balance sheet in the company's annual filing (2026-03-31). Each bar is the full balance sheet; "everything else" is what the filed total leaves after the named lines.

Where the cash went
Profit is an accounting figure; cash flow is what actually moved. Cash from running the business, plus or minus what was spent on or received from investments, plus or minus what came from or went to lenders and shareholders, equals the change in cash.

In FY26 the business itself brought in Rs 82 Cr, spent Rs 67 Cr on plant and equipment, and cash rose by Rs 1 Cr over the year.

From running the business
+82 Cr
Spent on or received from investing
-52 Cr
From or to lenders and shareholders
-29 Cr
Net change in cash
+1 Cr
Cash from operations for every Rs 100 of profit
Rs 205
FY25
Rs 261
FY26

Rs 100 or more means every rupee of reported profit arrived as cash.

Full financial year to 2026-03-31, from the company's cash flow statement.

Against its sector
Where this stock sits within its own sector on each measure. The marker is its position in the peer group and the notch is the sector median. A position is a fact about the cohort, not a view on the stock.
Healthcare Service Provider · 15
P/E45.44vs 27.62 median
Cheapest: KRSNAA 16.81Priciest: VIJAYA 76.73
Net margin10.78%vs 15.42% median
Lowest: HEALTHX -1.78%Highest: VIJAYA 21.87%
Revenue growth20.75%vs 22.44% median
Lowest: METROPOLIS 16.62%Highest: HEALTHX 49.73%
Compared against
3BBLACKBIOCHANDANCREDENTGAUDIUMIVFHEALTHXINVICTAKRSNAALALPATHLABMETROPOLISNEPHROPLUSNIDANONEGLOBALPRAMODINITHYROCAREVIJAYA

Median rather than average, so one loss-making or one very expensive peer cannot drag the reference. Valuation is shown without a colour verdict: a higher multiple can mean expensive, or faster growth expected, and only you can decide which.

Peers side by side
Every company in the same NSE industry group that we hold figures for, largest first. Tap any heading to sort by it. The same figures as the At a glance tiles, worked out the same way for every company.
Healthcare Service Provider · 9 shown
Company
LALPATHLAB
Dr. Lal Path Labs Ltd.
31,100 cr44.8x12.4x21.5%25.7%0.0018.9%+19.1%0.72%
VIJAYA
Vijaya Diagnostic Centre Limited
14,362 cr76.7x15.0x19.6%19.2%0.0021.9%+22.8%0.14%
METROPOLIS
Metropolis Healthcare Limited
10,989 cr22.8x7.3x13.3%15.7%0.0111.9%+16.6%0.19%
THYROCARE
Thyrocare Technologies Limited
7,491 cr27.6x12.8x30.0%33.6%0.0020.1%+24.3%1.98%
NEPHROPLUS
Nephrocare Health Services Limited
6,095 cr-5.5x-13.7%0.07--0.00%
SURAKSHA
Suraksha Diagnostic Limited
1,628 cr45.4x6.7x14.4%14.7%0.0110.8%+20.8%0.00%
KRSNAA
Krsnaa Diagnostics Limited
1,617 cr16.8x1.6x9.9%10.6%0.5511.9%+22.1%0.55%
HEALTHX
Health X Platform Limited
857 cr-1.3x-3.4%---1.8%+49.7%0.00%
GAUDIUMIVF
Gaudium IVF and Women Health Limited
674 cr-4.4x-23.1%0.15--0.00%

Swipe the table sideways for more columns. Tap a heading to sort. A dash means the figure is not filed or cannot be worked out for that company. A bigger cohort is cut to its 40 largest companies.

The business
Sales and net profit from the company's own filings, by financial year or by quarter. Hover any bar for that period's complete figures including operating margin and the change against the comparable earlier period. The single TTM figure above is the sum of the last four quarters.
8 quarters
RevenueRs 88 Cr
Net profitRs 13 Cr
Sep 248 quarters filedJun 26

Each bar is one quarter as filed with the exchange, newest on the right, so the seasonal shape of the business is visible rather than smoothed away. Hover any quarter for its full figures and the change against the same quarter a year earlier. Revenue and profit are drawn on separate scales because they differ by an order of magnitude; reading one against the other would be misleading.

Technical snapshot
Momentum, trend and delivery-based conviction from the actual price and volume history.
EOD 26 Oct
RSI (14) - momentum
47.8Neutral
0 oversold3070overbought 100
Delivery % - genuine buying vs churn
43.8%Near average
today 43.8%20d avg 48.9%

The share of traded quantity that was actually delivered (not squared off intraday) - high delivery vs its 20-session average suggests real buying or holding, not just churn.

vs 50-DMA
-4.23%
vs 200-DMA
+9.58%
1-month
-12.02%
3-month
+23.60%
1-year
+4.16%
Realized vol (30d)
39.5%
Insider trading disclosures
Promoter, director and other insider trades in the company's own shares, as disclosed to the exchange under SEBI's insider-trading regulations - usually within a few days of the transaction.
last 18 months

Insider trading data unavailable.

Recent announcements
The company's own filings to the exchange - results, board meetings, investor calls - with a link to the source document.
last 6 months

Announcements unavailable.

Want to test a strategy on SURAKSHA?

Backtest an equity strategy on real market data, free - no card needed.

Start free

Equity price, fundamentals and realized volatility are end-of-day / quarterly from real market data. The option chain (PCR, max pain, expected move, IV, OI) is live from the exchange during market hours; outside them it shows the last session's close. Shareholding, insider trades and announcements are the company's own exchange filings. Analysis only, not investment advice.